Ahmadov, Ulvi http://orcid.org/0000-0002-8657-5192
Picard, Daniel
Bartl, Jasmin
Silginer, Manuela
Trajkovic-Arsic, Marija
Qin, Nan
Blümel, Lena
Wolter, Marietta
Lim, Jonathan K. M.
Pauck, David
Winkelkotte, Alina Marie
Melcher, Marlen
Langini, Maike http://orcid.org/0000-0001-8622-3261
Marquardt, Viktoria
Sander, Felix
Stefanski, Anja
Steltgens, Sascha
Hassiepen, Christina
Kaufhold, Anna
Meyer, Frauke-Dorothee
Seibt, Annette
Kleinesudeik, Lara
Hain, Anika
Münk, Carsten
Knobbe-Thomsen, Christiane Brigitte
Schramm, Alexander
Fischer, Ute
Leprivier, Gabriel http://orcid.org/0000-0002-2299-8989
Stühler, Kai
Fulda, Simone http://orcid.org/0000-0002-0459-6417
Siveke, Jens T.
Distelmaier, Felix
Borkhardt, Arndt http://orcid.org/0000-0002-6121-4737
Weller, Michael http://orcid.org/0000-0002-1748-174X
Roth, Patrick
Reifenberger, Guido
Remke, Marc
Funding for this research was provided by:
Deutsche Krebshilfe (70112505)
Deutsche Forschungsgemeinschaft (SI1549/3-1, SI1549/4-1, RE2857/2-1, RE938/4-1, RE938/4-1, RE2857/2-1, RE2857/4-1(KFO337))
supported by the German Cancer Consortium
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF 310030E_170717, SNF 310030E_170717)
Article History
Received: 13 July 2020
Revised: 18 June 2021
Accepted: 22 July 2021
First Online: 28 September 2021
Ethics statement
: All animal experiments were performed in accordance with the guidelines of Swiss federal law on animal protection. No human subjects were part of this study.
: G.R. has received honoraria for advisory boards from Abbvie. M.W. has received research grants from Abbvie, Adastra, Bristol Meyer Squibb (BMS), Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Piqur and Roche, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, Bristol Meyer Squibb (BMS), Celgene, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen. P.R. has received honoraria for advisory board participation and lectures from Bristol-Myers Squibb, Covagen, Debiopharm, Medac, Merck, MSD, Novocure, QED, Roche and Virometix. C.M. is supported by the Heinz Ansmann foundation. JTS reports the following disclosures: Bristol-Myers Sqibb, Celgene, Roche (Research Funding); AstraZeneca, Bristol-Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (Consulting or advisory role); AstraZeneca, Aurikamed, Baxalta, Bristol Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Shire (honoraria); minor equity in iTheranostics and Pharma15 (<3%) and member of the Board of Directors for Pharma15, all outside the submitted work. The other authors report no conflict of interest.